ArticleBMC veterinary research2025
Lattice radiation therapy for canine sinonasal carcinoma: feasibility study of spatially fractionated radiotherapy using volumetric modulated arc therapy.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiation in Veterinary Practice: Paradigm Shift Toward Precision and Curative Approaches.Life (Basel, Switzerland) · 2026Review
- SFRT alleviates symptoms associated with bulky advanced cancer: a retrospective single-center cohort analysis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLattice radiotherapy (LRT) administers spatially fractionated doses to a tumor volume with the intent to induce beneficial anti-tumor host responses and avoid normal tissue damage. This study investigated feasibility of LRT for canine sinonasal carcinoma (SC) using volumetric modulated arc therapy (VMAT), aiming to achieve the following criteria: (1) place ≥ 3 vertices of high dose "peak" regions within the gross target volume (GTV) separated by low dose "valley" regions; (2) achieve a 3:1 and 5:1 peak-to-valley dose ratios (PVDR); (3) meet organ at risk (OAR) dose constraints; (4) meet quality assurance (QA) standards. A secondary aim was to assess the impact of dose calculation algorithms and grid size on dosimetry. The peak vertices were placed manually as 5 mm 3D spheres within the GTV. Treatment plans were initially optimized and calculated on Eclipse using Acuros with 2.5 mm grid size and underwent QA using Varian's Portal Dosimetry (3 mm/3%). Plans were then recalculated without re-optimization comparing Acuros XB (AXB) and anisotropic analytical algorithm (AAA) with variable grid sizes, to compare doses estimated for peak and valley lattice target volume and OARs.
resultsTwenty plans were generated from 10 image sets from dogs with SC. In all cases, (1) placement of ≥ 3 vertices was possible, with a median center-to-center distance of 30 mm (range: 26-41 mm); (2) achieved both 3:1 and 5:1 PDVR; (3) plans met OAR constraints; (4) all plans passed QA with gamma index > 95%. When comparing calculation algorithms with a consistent grid size, AAA overestimated the dose in both peak and valley regions compared to AXB. When using AXB, increasing the dose calculation grid size from 1.0 mm to 2.0 mm and 2.5 mm led to underestimation of the lattice metrics and overestimation of the valley dose, ultimately resulting in a reduced calculated PVDR. These deviations were not detected on standard clinical QA with portal dosimetry.
conclusionVMAT LRT planning and delivery is feasible for canine SC. This data suggests that the predicted-and consequently, reported-lattice target metrics can vary depending on specific treatment planning software settings. Further investigations could define the most appropriate QA approach for high-resolution LRT plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.